3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
1
Status
Withdrawn
4
Unknown
3
Terminated
3
Recruiting
3
Completed
3
Active not recruiting
3
Not yet recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Meningioma
1
Ependymoma
1
Interventions
pembrolizumab
219
Carboplatin
218
Specimen Handling
198
Cisplatin
188
Magnetic Resonance Spectroscopy
168
Radiotherapy
152
Bevacizumab
142
Gemcitabine
135
Cyclophosphamide
133
Drug Therapy
118
Capecitabine
118
Paclitaxel
112
Oxaliplatin
110
Biopsy
107
venetoclax
102
Nivolumab
101
Rituximab
83
tislelizumab
81
durvalumab
81
toripalimab
77
Fluorouracil
73
Etoposide
72
Dexamethasone
70
sintilimab
67
Radiosurgery
67
Docetaxel
67
Pemetrexed
65
atezolizumab
64
Azacitidine
63
Injections
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
brigatinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled
NCT04322890
2024-10-22
PIKACHU
Hunan Province Tumor Hospital
Phase 2
Recruiting
6,000 enrolled
NCT05014464
2024-09-20
ATPase
Hunan Province Tumor Hospital
Phase 2
Recruiting
90 enrolled